Last reviewed · How we verify
Mycobacterium w immunotherapy
Mycobacterium w is a heat-killed mycobacterial immunotherapy that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.
Mycobacterium w is a heat-killed mycobacterial immunotherapy that stimulates innate and adaptive immune responses to enhance anti-tumor immunity. Used for Tuberculosis (TB) as adjunctive immunotherapy, Advanced malignancies (under investigation in Phase 3).
At a glance
| Generic name | Mycobacterium w immunotherapy |
|---|---|
| Also known as | Immuvac |
| Sponsor | University of Cape Town |
| Drug class | Mycobacterial immunotherapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Mycobacterium w contains immunogenic mycobacterial antigens that activate pattern recognition receptors and dendritic cells, promoting Th1 and CD8+ T cell responses. This approach aims to boost the body's own immune system to recognize and eliminate cancer cells, potentially synergizing with checkpoint inhibitors or serving as a standalone immunotherapeutic agent.
Approved indications
- Tuberculosis (TB) as adjunctive immunotherapy
- Advanced malignancies (under investigation in Phase 3)
Common side effects
- Local injection site reactions
- Fever
- Fatigue
- Hypersensitivity reactions
Key clinical trials
- Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder (PHASE2)
- A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycobacterium w immunotherapy CI brief — competitive landscape report
- Mycobacterium w immunotherapy updates RSS · CI watch RSS
- University of Cape Town portfolio CI